Company takes canine cancer drug off market to study dosing
Posted March 15, 2017
Oasmia Pharmaceutical AB has taken a canine cancer drug, Paccal Vet, or paclitaxel for injection, off the market to study lowering the dose to reduce adverse effects. At the company’s request, the Food and Drug Administration has withdrawn conditional approval of the drug for use in dogs.
Paccal Vet is intended to treat certain mammary and squamous cell carcinomas in dogs that have not received chemotherapy or radiation therapy. Previously, Paccal Vet was available to a limited number of veterinary oncologists. Oasmia anticipates that by lowering the dose to reduce adverse effects, the product will become more attractive to veterinarians and pet owners. The company plans a proof-of-concept and dose-intensity study.
Related JAVMA content: